{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T22:52:43Z","timestamp":1792709563469,"version":"4.5.0"},"reference-count":48,"publisher":"Elsevier BV","issue":"19","content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2014,4]]},"DOI":"10.1016\/j.vaccine.2013.10.017","type":"journal-article","created":{"date-parts":[[2013,10,12]],"date-time":"2013-10-12T05:45:23Z","timestamp":1381556723000},"page":"2251-2259","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":84,"title":["Safety and immunogenicity of a plant-produced recombinant monomer hemagglutinin-based influenza vaccine derived from influenza A (H1N1)pdm09 virus: A Phase 1 dose-escalation study in healthy adults"],"prefix":"10.1016","volume":"32","author":[{"given":"James F.","family":"Cummings","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melanie L.","family":"Guerrero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James E.","family":"Moon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paige","family":"Waterman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robin K.","family":"Nielsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stacie","family":"Jefferson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F. Liaini","family":"Gross","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathy","family":"Hancock","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacqueline M.","family":"Katz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vidadi","family":"Yusibov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2013.10.017_bib0005","series-title":"Influenza (Seasonal). Fact sheet \u2116 211","author":"World Health Organization Media Centre","year":"2009"},{"key":"10.1016\/j.vaccine.2013.10.017_bib0010","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1126\/science.1176225","article-title":"Antigenic and genetic characteristics of swine-origin 2009 A(H1N1) influenza viruses circulating in humans","volume":"325","author":"Garten","year":"2009","journal-title":"Science"},{"issue":"25","key":"10.1016\/j.vaccine.2013.10.017_bib0015","doi-asserted-by":"crossref","first-page":"2605","DOI":"10.1056\/NEJMoa0903810","article-title":"Emergence of a novel swine-origin influenza A (H1N1) virus in humans","volume":"360","author":"Novel Swine-Origin Influenza A (H1N1) Virus Investigation Team","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2013.10.017_bib0020","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.1056\/NEJMoa0906453","article-title":"Cross-reactive antibody responses to the 2009 pandemic H1N1 influenza virus","volume":"361","author":"Hancock","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2013.10.017_bib0025","series-title":"WHO D-G statement","year":"2009"},{"issue":"3","key":"10.1016\/j.vaccine.2013.10.017_bib0030","first-page":"17","article-title":"Egg-based production of influenza vaccine: 30 years of commercial experience","volume":"36","author":"Matthews","year":"2006","journal-title":"The Bridge (Nat Acad Eng)"},{"key":"10.1016\/j.vaccine.2013.10.017_bib0035","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/B978-0-12-385034-8.00003-X","article-title":"Influenza vaccines: the good, the bad, and the eggs","volume":"77","author":"Schultz-Cherry","year":"2010","journal-title":"Adv Virus Res"},{"issue":"49","key":"10.1016\/j.vaccine.2013.10.017_bib0040","doi-asserted-by":"crossref","first-page":"9159","DOI":"10.1016\/j.vaccine.2011.08.008","article-title":"A systematic review of the evidence on the effectiveness and risks of inactivated influenza vaccines in different target groups","volume":"29","author":"Michiels","year":"2011","journal-title":"Vaccine"},{"issue":"1","key":"10.1016\/j.vaccine.2013.10.017_bib0045","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/S1473-3099(11)70295-X","article-title":"Efficacy and effectiveness of influenza vaccines: a systematic review and meta-analysis","volume":"12","author":"Osterholm","year":"2012","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.vaccine.2013.10.017_bib0050","doi-asserted-by":"crossref","first-page":"2405","DOI":"10.1056\/NEJMoa0907413","article-title":"Response to a monovalent 2009 influenza A (H1N1) vaccine","volume":"361","author":"Greenberg","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2013.10.017_bib0055","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/S0140-6736(09)62003-1","article-title":"Safety and immunogenicity of 2009 pandemic influenza A H1N1 vaccines in China: a multicentre, double-blind, randomised, placebo-controlled trial","volume":"375","author":"Liang","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2013.10.017_bib0060","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/S0140-6736(09)62026-2","article-title":"Immune response after a single vaccination against 2009 influenza A H1N1 in USA: a preliminary report of two randomised controlled phase 2 trials","volume":"375","author":"Plennevaux","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2013.10.017_bib0065","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1086\/656601","article-title":"A single dose of unadjuvanted novel 2009 H1N1 vaccine is immunogenic and well tolerated in young and elderly adults","volume":"202","author":"Talaat","year":"2010","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2013.10.017_bib0070","doi-asserted-by":"crossref","first-page":"2424","DOI":"10.1056\/NEJMoa0907650","article-title":"Trial of 2009 influenza A (H1N1) monovalent MF59-adjuvanted vaccine","volume":"361","author":"Clark","year":"2009","journal-title":"N Engl J Med"},{"issue":"30","key":"10.1016\/j.vaccine.2013.10.017_bib0075","doi-asserted-by":"crossref","first-page":"4771","DOI":"10.1016\/j.vaccine.2010.04.093","article-title":"Recombinant H1N1 virus-like particle vaccine elicits protective immunity in ferrets against the 2009 pandemic H1N1 influenza virus","volume":"28","author":"Pushko","year":"2010","journal-title":"Vaccine"},{"issue":"44","key":"10.1016\/j.vaccine.2013.10.017_bib0080","doi-asserted-by":"crossref","first-page":"7826","DOI":"10.1016\/j.vaccine.2011.07.099","article-title":"Safety and immunogenicity of a virus-like particle pandemic influenza A (H1N1) 2009 vaccine in a blinded, randomized, placebo-controlled trial of adults in Mexico","volume":"29","author":"L\u00f3pez-Mac\u00edas","year":"2011","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2013.10.017_bib0085","series-title":"White Paper","author":"Protein Sciences Corp","year":"2011"},{"key":"10.1016\/j.vaccine.2013.10.017_bib0090","doi-asserted-by":"crossref","first-page":"313","DOI":"10.4161\/hv.7.3.14207","article-title":"Clinical development of plant-produced recombinant pharmaceuticals: vaccines, antibodies and beyond","volume":"7","author":"Yusibov","year":"2011","journal-title":"Hum Vaccin"},{"issue":"8","key":"10.1016\/j.vaccine.2013.10.017_bib0095","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1586\/14760584.7.8.1173","article-title":"Recent progress in the development of plant derived vaccines","volume":"7","author":"Yusibov","year":"2008","journal-title":"Expert Rev Vaccines"},{"issue":"6","key":"10.1016\/j.vaccine.2013.10.017_bib0100","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1016\/j.biotechadv.2009.06.004","article-title":"Plants as bioreactors: recent developments and emerging opportunities","volume":"27","author":"Sharma","year":"2009","journal-title":"Biotechnol Adv"},{"key":"10.1016\/j.vaccine.2013.10.017_bib0105","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1111\/j.1467-7652.2009.00496.x","article-title":"The production of hemagglutinin-based virus-like particles in plants: a rapid, efficient and safe response to pandemic influenza","volume":"8","author":"D\u2019Aoust","year":"2010","journal-title":"Plant Biotechnol J"},{"issue":"5","key":"10.1016\/j.vaccine.2013.10.017_bib0110","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1111\/j.1467-7652.2010.00507.x","article-title":"Plant-made vaccines for humans and animals","volume":"8","author":"Rybicki","year":"2010","journal-title":"Plant Biotechnol J"},{"issue":"16","key":"10.1016\/j.vaccine.2013.10.017_bib0115","doi-asserted-by":"crossref","first-page":"3111","DOI":"10.1016\/j.vaccine.2007.01.068","article-title":"Immunogenicity of a subunit vaccine against Bacillus anthracis","volume":"25","author":"Chichester","year":"2007","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2013.10.017_bib0120","doi-asserted-by":"crossref","first-page":"3014","DOI":"10.1016\/j.vaccine.2007.01.017","article-title":"A plant-produced plague vaccine candidate confers protection to monkeys","volume":"25","author":"Mett","year":"2007","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2013.10.017_bib0125","doi-asserted-by":"crossref","first-page":"2930","DOI":"10.1016\/j.vaccine.2008.03.045","article-title":"Plant-expressed HA as a seasonal influenza vaccine candidate","volume":"26","author":"Shoji","year":"2008","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2013.10.017_bib0130","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1016\/j.vaccine.2008.11.108","article-title":"Plant-derived hemagglutinin protects ferrets against challenge infection with the A\/Indonesia\/05\/05 strain of avian influenza","volume":"27","author":"Shoji","year":"2009","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2013.10.017_bib0135","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1111\/j.1750-2659.2011.00295.x","article-title":"A plant-based system for rapid production of influenza vaccine antigens","volume":"6","author":"Shoji","year":"2012","journal-title":"Influenza Other Respi Viruses"},{"issue":"9","key":"10.1016\/j.vaccine.2013.10.017_bib0140","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1111\/j.1467-7652.2008.00384.x","article-title":"Influenza virus-like particles produced by transient expression in Nicotiana benthamiana induce a protective immune response against a lethal viral challenge in mice","volume":"6","author":"D\u2019Aoust","year":"2008","journal-title":"Plant Biotechnol J"},{"issue":"2","key":"10.1016\/j.vaccine.2013.10.017_bib0145","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1089\/jir.2007.0073","article-title":"Novel controlled-release Lemna-derived IFN-alpha2b (Locteron): pharmacokinetics, pharmacodynamics, and tolerability in a phase I clinical trial","volume":"28","author":"De Leede","year":"2008","journal-title":"J Interferon Cytokine Res"},{"issue":"29","key":"10.1016\/j.vaccine.2013.10.017_bib0150","doi-asserted-by":"crossref","first-page":"10131","DOI":"10.1073\/pnas.0803636105","article-title":"Plant-produced idiotype vaccines for the treatment of non-Hodgkin's lymphoma: safety and immunogenicity in a phase I clinical study","volume":"105","author":"McCormick","year":"2008","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"12","key":"10.1016\/j.vaccine.2013.10.017_bib0155","doi-asserted-by":"crossref","first-page":"e15559","DOI":"10.1371\/journal.pone.0015559","article-title":"Preclinical and clinical development of plant-made virus-like particle vaccine against avian H5N1 influenza","volume":"5","author":"Landry","year":"2010","journal-title":"PLoS ONE"},{"key":"10.1016\/j.vaccine.2013.10.017_bib0160","series-title":"Medicago Inc News release","year":"2011"},{"issue":"22","key":"10.1016\/j.vaccine.2013.10.017_bib0165","doi-asserted-by":"crossref","first-page":"5767","DOI":"10.1182\/blood-2011-07-366955","article-title":"Pivotal trial with plant cell-expressed recombinant glucocerebrosidase, taliglucerase alfa, a novel enzyme replacement therapy for Gaucher disease","volume":"118","author":"Zimran","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.vaccine.2013.10.017_bib0170","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1111\/j.1750-2659.2006.00005.x","article-title":"A launch vector for the production of vaccine antigens in plants","volume":"1","author":"Musiychuk","year":"2007","journal-title":"Influenza Other Respi Viruses"},{"issue":"Suppl.","key":"10.1016\/j.vaccine.2013.10.017_bib0175","doi-asserted-by":"crossref","first-page":"41","DOI":"10.4161\/hv.7.0.14561","article-title":"Plant-based rapid production of recombinant subunit hemagglutinin vaccines targeting H1N1 and H5N1 influenza","volume":"7","author":"Shoji","year":"2011","journal-title":"Hum Vaccin"},{"key":"10.1016\/j.vaccine.2013.10.017_bib0180","series-title":"Manual for the laboratory diagnosis and virological surveillance of influenza","author":"World Health Organization WHO Global Influenza Surveillance Network","year":"2011"},{"key":"10.1016\/j.vaccine.2013.10.017_bib0185","series-title":"Guidance for industry toxicity grading scale for healthy adult and adolescent volunteers enrolled in preventive vaccine clinical trials","year":"2007"},{"key":"10.1016\/j.vaccine.2013.10.017_bib0190","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.vaccine.2009.09.103","article-title":"Safety and immunogenicity of whole-virus, alum-adjuvanted whole-virus, virosomal, and whole-virus intradermal influenza A\/H9N2 vaccine formulations","volume":"28","author":"Nicholson","year":"2010","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2013.10.017_bib0195","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1086\/655226","article-title":"A rapid immune response to 2009 influenza A(H1N1) vaccines in adults: a randomized, double-blind, controlled trial","volume":"202","author":"Wu","year":"2010","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2013.10.017_bib0200","doi-asserted-by":"crossref","first-page":"2414","DOI":"10.1056\/NEJMoa0908535","article-title":"A novel influenza A (H1N1) vaccine in various age groups","volume":"361","author":"Zhu","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2013.10.017_bib0205","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1086\/527489","article-title":"Effects of adjuvants on the safety and immunogenicity of an avian influenza H5N1 vaccine in adults","volume":"197","author":"Bernstein","year":"2008","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2013.10.017_bib0210","doi-asserted-by":"crossref","first-page":"5091","DOI":"10.1016\/j.vaccine.2009.06.057","article-title":"Safety and immunogenicity of a subvirion inactivated influenza A\/H5N1 vaccine with or without aluminum hydroxide among healthy elderly adults","volume":"27","author":"Brady","year":"2009","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2013.10.017_bib0215","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1016\/S0140-6736(06)68656-X","article-title":"Safety and immunogenicity of an inactivated split-virion influenza A\/Vietnam\/1194\/2004 (H5N1) vaccine: phase I randomised trial","volume":"367","author":"Bresson","year":"2006","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2013.10.017_bib0220","doi-asserted-by":"crossref","first-page":"2573","DOI":"10.1056\/NEJMoa073121","article-title":"A clinical trial of a whole-virus H5N1 vaccine derived from cell culture","volume":"358","author":"Ehrlich","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2013.10.017_bib0225","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1086\/592172","article-title":"Safety and immunogenicity of an inactivated influenza A\/H5N1 vaccine given with or without aluminum hydroxide to healthy adults: results of a phase I\u2013II randomized clinical trial","volume":"198","author":"Keitel","year":"2008","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2013.10.017_bib0230","doi-asserted-by":"crossref","first-page":"6642","DOI":"10.1016\/j.vaccine.2009.03.015","article-title":"Safety and immunogenicity of inactivated, Vero cell culture-derived whole virus influenza A\/H5N1 vaccine given alone or with aluminum hydroxide adjuvant in healthy adults","volume":"27","author":"Keitel","year":"2009","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2013.10.017_bib0235","doi-asserted-by":"crossref","first-page":"4160","DOI":"10.1016\/j.vaccine.2008.05.077","article-title":"Phase I and II randomised trials of the safety and immunogenicity of a prototype adjuvanted inactivated split-virus influenza A (H5N1) vaccine in healthy adults","volume":"26","author":"Nolan","year":"2008","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2013.10.017_bib0240","doi-asserted-by":"crossref","first-page":"2062","DOI":"10.1002\/eji.1830260915","article-title":"In interleukin-4-deficient mice, alum not only generates T helper 1 responses equivalent to Freud's complete adjuvant, but continues to induce T helper 2 cytokine production","volume":"26","author":"Brewer","year":"1996","journal-title":"Eur J Immunol"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X13013819?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X13013819?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,10,12]],"date-time":"2018-10-12T06:51:05Z","timestamp":1539327065000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X13013819"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,4]]},"references-count":48,"journal-issue":{"issue":"19","published-print":{"date-parts":[[2014,4]]}},"alternative-id":["S0264410X13013819"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2013.10.017","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2014,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Safety and immunogenicity of a plant-produced recombinant monomer hemagglutinin-based influenza vaccine derived from influenza A (H1N1)pdm09 virus: A Phase 1 dose-escalation study in healthy adults","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2013.10.017","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}